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Abstract
Lecithins (E 322) were re-evaluated in 2017 by the former EFSA Panel on Food Additives and Nutrient
sources added to Food (ANS). As follow-up to that assessment, the Panel on Food Additives and
Flavourings (FAF) was requested to assess the safety of lecithins (E 322) for uses as food additive in
food for infants below 16 weeks of age belonging to food categories 13.1.1 and 13.1.5.1 and as carry
over in line with Annex III to Regulation (EC) No 1333/2008. In addition, the FAF Panel was requested
to address the issues identified during the re-evaluation of the food additive (E 322). The process
involved the publication of a call for data to allow the interested business operators to provide the
requested information to complete the risk assessment. Based on the information submitted in
response to the call for data, the FAF Panel considered it feasible to amend the EU specifications, in
particular for the toxic elements arsenic, lead, mercury and introduce new specifications for cadmium
and microbiological criteria. The safety issue identified by the ANS Panel in 2017 concerned potential
neurodevelopmental effects. For the reason that choline is a precursor of the neurotransmitter
acetylcholine, the Panel considered it appropriate to address the safety of lecithins (E 322) as food
additive in infant formula used in infants below the age of 16 weeks by comparing the concentration of
choline in human milk with that in the formula. The Panel concluded that the intake of lecithins
(E 322) as a food additive in infant formula belonging to FC 13.1.1 or in food for special medical
purposes belonging to FC 13.1.5.1 does not raise safety concerns up to the maximum permitted level
(MPL) of lecithins (E 322).
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Summary
In accordance with Regulation (EU) No 257/2010, the European Food Safety Authority (EFSA) is
currently re-evaluating the safety of food additives already permitted in the Union before 20 January
2009 and issuing scientific opinions on their safety when used in food as per Annexes II and III to
Regulation (EC) No 1333/2008. The risk assessment approach followed in the re-evaluation has not
covered the use of food additives in food for infants below 12 weeks of age. Additionally, while
re-evaluating the safety of food additives referred to above, EFSA identified some concerns, namely
(1) data gaps that have triggered recommendations in the published scientific opinions; and/or (2)
data gaps that have increased uncertainties linked to the risk assessment and/or which prevented the
Panel from concluding on some aspects of it.
On 31 May 2017, EFSA published a guidance on the risk assessment of substances present in food
intended for infants below 16 weeks of age, thus enabling EFSA to assess the safety of food additive
used in food for infants below this age. The age up to 16 weeks was selected in the guidance because
infants are exposed to formula feeding until this age as the only source of food since complementary
feeding is not supposed to be introduced before.
As follow-up of the above, this Opinion addresses the data gaps previously identified during the re-
evaluation of lecithins (E 322) as food additive, the recommendations expressed by the ANS Panel and
the safety in the special subpopulation of infants below 16 weeks of age.
The process followed involved the publication of a dedicated call for data allowing all interested
business operators to provide the requested information a) for closing the data gaps and addressing
the recommendations and b) for completing the assessment and to confirm that the additive is present
as food additive in food for infants below 16 weeks of age belonging to food categories 13.1.1 (infant
formulae as defined by Commission Delegated Regulation (EU) 2016/127) and 13.1.5.1 (dietary foods
for infants for special medical purposes and special formulae for infants) and as carry over in line with
Annex III to Regulation (EC) No 1333/2008.
The data submitted in response to the call for data on lecithins (E 322) included technical
information, information on the levels of use and literature studies. In addition, the interested business
operator provided a comparison between the levels of choline and phospholipids in the infant formulae
and in the maternal milk.
Lecithins (E 322) are identified as mixtures or fractions of phosphatides obtained by physical
procedures from animal or vegetable foodstuffs. Specifications for lecithins (E 322) have been defined
in Commission Regulation (EU) No 231/2012.
The Panel considered it feasible to amend the EU specifications based on the information submitted
in response to the call for data. This refers to lowering existing limits for the toxic elements arsenic,
lead and mercury as well as introducing new specifications for cadmium and microbiological criteria.
According to Annex II of Regulation (EC) No 1333/2008, lecithins (E 322) are permitted in food
categories 13.1.1 of infant formulae and 13.1.5.1 of dietary foods for infants for special medical
purposes and special formulae (FSMP) for infants at a maximum level of 1,000 mg/L. Lecithins (E 322)
are also authorised as food additives in all nutrients intended to be used in foods for infants and young
children according to Annex III, Part 5, Section B of Regulation (EC) No 1333/2008 provided that the
maximum level defined in Part E of Annex II is not exceeded.
Based on data submitted by SNE members, lecithins (E 322) are used in infant formulae for infants
below 16 weeks of age and in special formulae for infants of that age under special medical conditions
at levels of up to 1,000 mg/L, and are thus in compliance with maximum permissible levels in the EU.
For infants below 16 weeks of age consuming infant formulae (FC 13.1.1) or infant food for special
medical purposes (FSMP) (FC 13.1.5.1), in the regulatory maximum level exposure assessment
scenario, mean exposure to lecithins (E 322) was estimated to be 200 mg/kg body weight (bw) per
day while the high level was estimated at 260 mg/kg bw per day. In the refined scenario, exposure
was the same using the maximum reported levels by the interested business operators (for both FC
13.1.1 and 13.1.5.1); while using the mean reported levels by the interested business operators,
refined exposure is estimated at 62 mg/kg bw per day at the mean (81 mg/kg bw per day at the p95)
for FC 13.1.1 and at 180 mg/kg bw per day at the mean (234 mg/kg bw per day at the p95) for FC
13.1.5.1.
In the re-evaluation of lecithins, the acute toxicity of lecithins (E 322) in mice, rats and rabbits was
considered as low. In addition, the available subchronic and chronic toxicity studies did not report any
adverse effect, even at the highest doses tested. No carcinogenic effects were reported in rats, even
at the highest dose tested. The ANS Panel considered the available genotoxicity data on lecithins
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(E 322) to be sufficient to conclude that there is no concern with respect to genotoxicity. Adverse
effects were not observed in the developmental toxicity studies performed in mice, rat and rabbits up
to the highest dose tested. However, the Panel noted that reproductive toxicity studies were not
available. The ANS Panel considered the available data addressing neurodevelopment inadequate and
concluded that a study with lecithins (E 322) in compliance with the current OECD TG 426 would be
warranted.
The main safety issue identified in the EFSA ANS Opinion concerned indications that the
development of the brain was altered at concentrations in the diet of 5% soya lecithins and higher
during gestation, lactation and post-weaning period observed in toxicity studies. It has to be noted,
however, that these studies had limitations which precluded firm conclusions by the ANS Panel. The
studies provided during the call for data did not contribute to assessment of potential
neurodevelopmental effects because this endpoint has not been addressed in the studies. Specific
studies in infants were not provided and the data from the post-marketing surveillance studies did not
allow to make firm conclusions on the safety of lecithins (E 322) in infant formula. In line with the
recommendations from the ANS Panel former assessment, the FAF Panel considered that the
appropriate approach to be taken for the safety assessment of lecithins (E 322) as food additive in
infant formula used in infants below the age of 16 weeks was to compare the concentration of choline
in human milk with that in the formula.
From the information provided by the interested business operator, the mean content of total
choline in formula (225 mg/L) is around 62% higher than that in human milk (138 mg/L). However,
the mean content of choline released from lecithins in infant formula (12 mg/L) represents only 8.7%
of the mean content of total choline in mature human milk. The same conclusion applies at the MPL of
1,000 mg/L which could contribute to 21 mg/L of choline. Most (nearly 75%) of the total choline
content in infant formula is derived from the addition of choline as nutrient. The mean content of
choline in the formulae is in the range of the adequate intake (AI).
Considering the data submitted by interested business operators and the considerations from the
Panel, a revision of the existing EU specifications for lecithins (E 322) has been recommended (see
Table 12).
The choline released from lecithins (E 322) is a minor contributor (around 8.7% as the mean) of
the total content of choline of the formula and does not raise concern at the current use levels
including the MPL for lecithins (E 322). Most of the choline in the formula is due to the choline added
as a nutrient. In addition, it can be stated that the mean content of choline is in the range of the
adequate intake level (AI). The Panel concluded that the intake of lecithins (E 322) as a food additive
in infant formula belonging to FC 13.1.1 or in food for special medical purposes belonging to FC
13.1.5.1 does not raise safety concerns up to the MPL of lecithins (E 322).
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1. Introduction
The present opinion deals with:
• the risk assessment of lecithins (E 322) in food for infants below 16 weeks of age in the food
categories 13.1.1 (Infant formulae as defined by Commission Delegated Regulation (EU) 2016/
127/EC1) and 13.1.5.1 (Dietary foods for infants for special medical purposes and special
formulae for infants) as defined in Annex II and III to Regulation (EC) No 1333/2008 on food
additives
• the follow-up on issues that have been expressed in the conclusions and recommendations of
the Scientific Opinion on the re-evaluation of lecithins (E 322) as a food additive (EFSA ANS
Panel, 2017)
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background
The composition of food intended for infants and young children, as defined by Regulation (EU) No
609/20132, is regulated at EU level and such rules include requirements concerning the use of
substances as food additives.
The use of food additives is regulated by Regulation (EC) No 1333/2008 on food additives. Only
food additives that are included in the Union list, in particular in Annex II and III to that Regulation,
may be placed on the market and used in food under the conditions of use specified therein.
In accordance with Regulation (EU) No 257/20103, EFSA is currently re-evaluating the safety of
food additives already permitted in the Union before 20 January 2009 and issuing scientific opinions on
their safety when used in food as per Annexes II and III to Regulation (EC) No 1333/2008. However,
the risk assessment approach followed until now has not covered the use of food additives in food for
infants below 12 weeks of age. Consequently, EFSA published several scientific opinions on the re-
evaluation of the safety of food additives permitted in food category 13.1 but not addressing their use
in food for infants below 12 weeks of age.
In addition, in these opinions EFSA identified some concerns, namely 1) Data gaps that have
triggered recommendations in the (to be) published scientific opinions, and/or; 2) Data gaps that have
increased uncertainties linked to the risk assessment and/or which prevented the EFSA from
concluding on some aspects of it.
On 31 May 2017, EFSA published a guidance document (EFSA Scientific Committee, 2017) on the
risk assessment of substances present in food intended for infants below 16 weeks of age, thus
enabling EFSA to assess the safety of food additives used in food for infants below 12 weeks of age.4
Now EFSA is expected to launch dedicated calls for data to be able to perform such risk assessments.
The EC considers it is more effective that EFSA, in the context of these dedicated calls for data,
also addresses all the issues and data gaps already identified in the relevant (to be) published scientific
opinions on the re-evaluation of the safety of food additives permitted in food category 13.1.
In accordance with the current EC approach for the follow-up of EFSA’s scientific opinions on the
re-evaluation of the safety of permitted food additives for which some concerns have been identified, a
specific call for data would be published by the EC on DG SANTE’s website5 on food additives and
additional (missing) information would then be provided by interested business operators to the EC.
However, for those scientific opinions on the re-evaluation of the safety of permitted food additives
in food category 13.1 for which the risk assessment does not address their uses in food for infants
1 Commission Delegated Regulation (EU) 2016/127/EC of 25 September 2015 supplementing Regulation (EU) No 609/2013 of
the European Parliament and of the Council as regards the specific compositional and information requirements for infant
formula and follow-on formula and as regards requirements on information relating to infant and young child feeding. OJ L 25,
2.2.2016, p. 1–29.
2 Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and
young children, food for special medical purposes, and total diet replacement for weight control and repealing Council Directive
92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of the
European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009. OJ L 181,
29.6.2013, p. 35–56.
3 Commission Regulation (EU) No 257/2010 of 25 March 2010 setting up a program for the re-evaluation of approved food
additives in accordance with Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food additives.
OJ L 80, 26.3.2010, p. 19–27.
4 See Section 1.1.3.
5 https://ec.europa.eu/food/safety/food_improvement_agents/additives/re-evaluation_en
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below 12 weeks of age and for which some concerns have been identified by EFSA, the EC considers
that for the sake of efficiency it would be appropriate to streamline the approach as described above.
Therefore, the EC requests EFSA to address all the issues and data gaps already identified in the
relevant published scientific opinions of those food additives (or groups of additives that can be
addressed simultaneously) as part of the upcoming work on the safety assessment of food additives
uses in food for infants below 12 weeks of age.
This follow-up aims at completing the re-evaluation of the food additives in question for all food
categories, and includes calls for data covering the actual use and usage levels of food additives in
food for both infants below 12 or 16 weeks of age as well as for older infants, young children and
other groups of the population for which EFSA has already finalised its assessment.
The future evaluations of EFSA should systematically address the safety of use of food additives for
all age groups, including the infants below 12 or 16 weeks of age.
1.1.2. Terms of Reference
In accordance with Article 29(1)(a) of Regulation (EC) No 178/20026, and as part of EFSA’s work in
completing its risk assessments concerning the use of food additives in food for infants below 12
weeks of age,5 covered by the re-evaluation programme and its terms of reference, the European
Commission requests the European Food Safety Authority to address all the data gaps specified in the
recommendations made in this scientific opinions on the re-evaluation of the safety of food additives
permitted in food category 13.1 (food for infants and young children) of Annex II to Regulation (EC)
No 1333/2008.
1.1.3. Interpretation of Terms of reference
Before the publication of the EFSA Scientific Committee Guidance on the risk assessment of
substances present in food intended for infants below 16 weeks of age (EFSA Scientific Committee,
2017), EFSA has taken 12 weeks as a cut off age for the applicability of the safety assessment.
However, according to EFSA Scientific Committee (2017), the assessment will include infants up to 16
weeks of age because they are exposed to formula feeding until this age as the only source of food
since complementary feeding is not supposed to be introduced before this age (see EFSA Scientific
Committee, 2017).
This risk assessment addresses the use of lecithins (E 322) in their technological function as food
additive and not as a nutritional source of choline. However, it should be considered that choline is
released from E 322 adding to the content of total choline in the formula.
1.2. Previous evaluations of lecithins (E 322) for use in foods for infants
Lecithins (E 322) have been evaluated by the Scientific Committee on Food (SCF) in 1981 (SCF,
1982) and 1997 (SCF, 1997). In its assessment from 1981, SCF discussed hydrolysed lecithins and
their comparability to lecithins stating that ‘hydrolysed lecithin is produced in the gut as a result of
normal digestion. There appears to be no specific toxicological effect in rats due to feeding of
hydrolysed lecithins. This substance can therefore be regarded metabolically and toxicologically as an
alternative to lecithin’. In 1997, the SCF concluded that ‘the issue of lecithins and choline in infant
formulae should be considered further. However, in the context of carry-over levels of only 0.5 mg/kg,
the use of lecithins in nutrient preparations for infant formulae is acceptable and not likely to be of
concern’ (SCF, 1997). The SCF additionally noted that ‘In an earlier report (SCF, 1983) the Committee
considered lecithins as acceptable technological additives at levels up to 5 g/L. However, the Directive
on Additives Other Than Colours and Sweeteners lists the maximum level as 1 g/L. This reduction in
the maximum level was agreed during the negotiations on the draft Directive in response to a report
(UK Ministry of Agriculture Fisheries and Food, 1992) which recommended that the maximum level of
lecithins in infant formulae should be restricted to that of human milk (1 g/L). This recommendation
was based on studies which claimed neurobehavioural effects in the offspring of rats fed high doses of
lecithin. Although these studies were of poor quality, the report noted that large increases in plasma
choline could affect neurotransmission in the brain and that particular caution was needed in the infant
since the brain was still actively developing’.
6 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
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Lecithins (E 322) were evaluated also by JECFA in 1974 (JECFA, 1974a,b); JECFA did not specify a
numerical acceptable daily intake (ADI) (ADI ‘not limited’).
In 2014, the EFSA Panel on Dietetic Products, Nutrition and Allergies (EFSA NDA Panel, 2014)
prepared a scientific opinion on the evaluation of allergenic foods and food ingredients for labelling
purposes where the allergenicity of egg and soya lecithins were considered. The possibility of residual
allergenicity in food products manufactured using egg lecithins has been reported in a double-blind
placebo-controlled food challenge (DBPCFC). The prevalence of clinically confirmed soya allergy in
unselected populations in Europe appears to be low, although few studies are available. Soybeans and
eggs and products thereof (including lecithins) are listed in the Annex II of the Regulation No 1169/2011
as substances or products causing allergies or intolerances for which indication as allergens is mandatory.
1.3. Previous evaluations of choline
Dietary lecithins are known to be hydrolysed and liberate choline in humans.
In its scientific opinion on dietary reference values (DRV) for choline, the EFSA NDA Panel (2016)
considered dietary choline including choline compounds (e.g. glycerophosphocholine, phosphocholine,
phosphatidylcholine,7 sphingomyelin). The NDA Panel concluded that average requirements (ARs) and
population reference intakes (PRIs) for choline could not be derived for adults, infants and children,
and therefore defined adequate intakes (AIs).
Considering that there is no evidence for an insufficient choline intake of fully breast-fed infants
during the first 6 months of life, the amount of choline provided in human milk is considered to be
adequate (EFSA NDA Panel, 2016). Considering a choline concentration of 145 mg/L (average of two
studies on full-term infants) and assuming a mean milk transfer of 0.8 L/day during the first 6 months
of lactation in exclusively breastfeeding women, the estimated choline intake of fully breast-fed infants
during the first 6 months of life would be 116 mg/day, rounded up to 120 mg/day.
The SCF did not consider choline when setting tolerable upper intake levels (ULs) for vitamins and
minerals (2006). The US Institute of Medicine (IOM, 1998) set a UL for choline for adults, but no UL
was established for infants 0–12 months.
Choline is listed in Commission Delegated Regulation 2016/1278 on specific compositional and
information requirements for infant formula and follow-on formula and as regards requirements on
information relating to infant and young child feeding. The minimal and maximal content of choline in
infant formula is 20 and 50 mg/100 kcal, respectively. No minimal and maximal content of choline has
been set for follow-on formula.
1.4. Summary of the previous EFSA re-evaluation of lecithins (E 322) for
uses in food for all population groups except for infants below 12
weeks of age9
In its scientific opinion, the ANS Panel (EFSA ANS Panel, 2017) reviewed available technical,
biological and toxicological data on lecithins (E 322) when used as a food additive. They concluded
that there was no need for a numerical ADI for lecithins (E 322). The ANS Panel took into account
uses and use levels reported by the interested business operators and derived refined exposure
scenarios. They concluded that there was no safety concern for the general population (from more
than 1 year of age) for lecithins (E 322) food additive itself and for exposure to the choline that
derives from lecithins (E 322). Similarly, they concluded that there was no safety concern for lecithins
(E 322) nor for choline derived therefrom for infants (from 12 weeks up to 11 months of age).
Concerning infants above 12 weeks and young children consuming foods for special medical purposes,
the ANS Panel also concluded that there was no safety concern for lecithins (E 322) or for choline
derived therefrom.
7 A major component of lecithins (E 322).
8 Commission Delegated Regulation (EU) 2016/127 of 25 September 2015 supplementing Regulation (EU) No 609/2013 of the
European Parliament and of the Council as regards the specific compositional and information requirements for infant formula
and follow-on formula and as regards requirements on information relating to infant and young child feeding (Text with EEA
relevance) OJ L 25, 2.2.2016, p. 1–29.
9 According to the EFSA Scientific Committee Guidance (EFSA Scientific Committee, 2017) this opinion will include infants up to
16 weeks of age.
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The ANS Panel, however, considered that the conclusions reached on the re-evaluation of the food
additive were not applicable to the use of lecithins (E 322) in food for infants under the age of 12
weeks.10 They considered that these uses would require a specific risk assessment.
In addition, the ANS Panel drafted the following recommendations which are relevant for this
assessment:
• recommended that the maximum limits for the impurities of toxic elements (lead, mercury and
arsenic) in the EU specification for lecithins (E 322) should be revised in order to ensure that
lecithins (E 322) as a food additive will not be a significant source of exposure to those toxic
elements in food. The Panel also recommended that a limit for cadmium should be included in
the specifications.
• recommended the content of residual proteins in lecithins (E 322) should be reduced as much
as possible, since there are some case reports of hypersensitivity reactions associated with
soya and egg lecithins and the Panel considered that this hypersensitivity is due to the
presence of proteins.
• found the data available and the relevance of existing neurodevelopmental studies to be
inadequate and concluded that a study with lecithins (E 322) in compliance with the current
OECD TG 426 would be warranted.
• recommended that in case the food additive lecithins (E 322) is used in infant formulae and
follow-on formulae supplemented with choline or choline salts, the intake of choline from all
sources including the use of the food additive lecithins (E 322) via infant formulae (category
13.1.1), follow-on formulae (category 13.1.2) or other food should be in the order of the
adequate intake values defined by the EFSA NDA Panel (2016a).
In 2020, the FAF Panel issued a scientific opinion on the safety of a proposed amendment of the
specifications of the food additive lecithins (E 322) to include oat lecithin, an oat oil derived from water
and ethanol extraction of oat grain seeds and composed of polar lipids (≥ 35% w/w) and non-polar
lipids (55–65% w/w). In its scientific opinion, the Panel, however, recommended that the European
Commission considers including specifications for oat lecithin as a new food additive in Commission
Regulation (EU) No 231/2012 rather than amending the existing specifications of lecithins (E 322)
(EFSA FAF Panel, 2020).
2. Data and methodologies
2.1. Data
EFSA launched a public call for data11 to collect relevant information from the interested business
operators (see also Appendix A).
The Panel based its assessment on information submitted to EFSA following the public call for data,
information from previous evaluations and additional available literature up to 10 September 2020.
To verify the use of the food additive lecithins (E 322) in food products, the Mintel’s GNPD was
used. This database is an online database which monitors new introductions of packaged goods in the
market worldwide. It contains information of over 3 million food and beverage products of which more
than 1,100,000 are or have been available on the European food market. Mintel started covering EU’s
food markets in 1996, currently having 24 out of its 27 Member Countries, and Norway and UK
presented in the Mintel GNPD.
2.2. Methodologies
This opinion was formulated following the principles described in the EFSA Guidance on
transparency with regard to scientific aspects of risk assessment (EFSA Scientific Committee, 2009)
and following the relevant existing guidance documents from the EFSA Scientific Committee and in
particular the EFSA Guidance of the Scientific Committee on the risk assessment of substances present
in food intended for infants below 16 weeks of age (EFSA Scientific Committee, 2017).
10 According to the EFSA Scientific Committee Guidance (EFSA Scientific Committee, 2017), this opinion will include infants up to
16 weeks of age.
11 Call for technical and toxicological data on lecithins (E 322) as a food additive for uses in foods for all population groups
including infants below 16 weeks of age. Published: 18 July 2018. Available online: https://www.efsa.europa.eu/en/c
onsultations/call/call-technical-and-toxicological-data-lecithins-e-322-uses-foods
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In order to conclude on the safety of lecithins (E 322) for all population groups and to address data
gaps identified during the re-evaluation, the FAF Panel assessed the information provided:
• for the follow-up on issues that have been raised in the conclusions and recommendations of
the Scientific Opinion on the re-evaluation of lecithins (E 322) as a food additive (EFSA ANS
Panel, 2017); and
• the risk assessment of lecithins (E 322) in food for infants below 16 weeks of age in the food
categories 13.1.1 (infant formulae as defined by Commission Delegated Regulation (EU) 2016/
127/EC) and 13.1.5.1 (dietary foods for infants for special medical purposes and special
formulae for infants) as defined in Annexes II and III to Regulation (EC) No 1333/2008 on
food additives
When in animal studies, the test substance was administered in the feed or in drinking water, but
doses were not explicitly reported by the authors as mg/kg bw per day based on actual feed or water
consumption, the daily intake is calculated by the panel using the relevant default values. In case of
rodents, the values as indicated in the EFSA Scientific Committee Guidance document (EFSA Scientific
Committee, 2012) are applied. In the case of other animal species, the default values by JECFA (2000)
are used. In these cases, the dose was expressed as ‘equivalent to mg/kg bw per day’. If a
concentration in feed or drinking water was reported and the dose in mg/kg bw per day was
calculated (by the authors of the study report or the Panel) based on these reported concentrations
and on reported consumption data for feed or drinking water, the dose was expressed as ‘equal to
mg/kg bw per day’. When in human studies in adults (aged above 18 years), the dose of the test
substance administered was reported in mg/person per day, the dose in mg/kg bw per day was
calculated by the Panel using a body weight of 70 kg as default for the adult population as described
in the EFSA Scientific Committee Guidance document (EFSA Scientific Committee, 2012).
Dietary exposure to lecithins (E 322) from its use as a food additive in foods for infants below 16
weeks of age was estimated combining the mean and high level consumption values reported for the
period of 14–27 days of life which corresponds to 200 and 260 mL/kg bw per day (EFSA Scientific
Committee, 2017), respectively, with the maximum levels according to Annex II and Annex III, Part 5
Section B to Regulation (EC) No 1333/2008 and reported use levels submitted to EFSA following a call
for data. Different scenarios were used to calculate exposure (see Section 3.3.1). Uncertainties on the
exposure assessment were identified and discussed.
3. Assessment
3.1. Technical data
3.1.1. Identity of the substance
According to Commission Regulation (EU) No 231/201212, the food additive E 322 is named as
lecithins and the additive is identified as mixtures or fractions of phosphatides obtained by physical
procedures from animal or vegetable foodstuffs. They also include the corresponding hydrolysed
products. Commission Regulation No 231/2012 includes both types of lecithins (non-hydrolysed and
hydrolysed) under the same food additive designation (E 322). JECFA differentiates between them and
treats them as different food additives (INS 322i and INS 322ii) with distinct specifications (JECFA,
2007a,b).
The fatty acids in lecithins have variable carbon chain lengths; therefore, an exact molecular
formula and a molecular weight can only be given for individual components (see EFSA ANS Panel,
2017 and Figure 1).
12 Commission Regulation (EU) No 231/2012 of 9 March 2012 laying down specifications for food additives listed in Annexes II
and III to Regulation (EC) No 1333/2008 of the European Parliament and of the Council Text with EEA relevance. OJ L 83,
22.3.2012, p. 1–295.
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3.1.2. Specifications
The specifications for lecithins (E 322) as defined in the Commission Regulation (EU) No 231/2012
are listed in Table 1.
Figure 1: Structures of the main phospholipids in lecithins (E 322): phosphatidylcholine (1),
phosphatidylethanolamine (2), phosphatidylinositol (3), phosphatidylserine (4). If R1 = H,
the compound is phosphatidic acid (from EFSA ANS Panel, 2017). For more information on
the physical properties and the chemical composition and structure of lecithins (E 322) from
various sources such as soya bean oil, sunflower oil, rape seed oil, egg yolk, etc., the
reader is referred to the ANS Panel opinion (EFSA ANS Panel, 2017)
Table 1: Specifications for lecithins (E 322) according to Commission Regulation (EU) No 231/2012
Commission Regulation (EU) No 231/2012
Definition Lecithins are mixtures or fractions of phosphatides obtained by physical procedures
from animal or vegetable foodstuffs; they also include hydrolysed products obtained
through the use of harmless and appropriate enzymes. The final product must not show
any signs of residual enzyme activity. The lecithins may be slightly bleached in aqueous
medium by means of hydrogen peroxide. This oxidation must not chemically modify the
lecithin phosphatides
Assay Lecithins: not less than 60.0% of substances insoluble in acetone Hydrolysed lecithins:
not less than 56.0% of substances insoluble in acetone
Description Lecithins: brown liquid or viscous semi-liquid or powder
Hydrolysed lecithins: light brown to brown viscous liquid or paste
Identification






To a 800-mL beaker, add 500 mL of water (30–35°C). Then slowly add 50 mL of the
sample with constant stirring. Hydrolysed lecithin will form a homogeneous emulsion.
Non-hydrolysed lecithin will form a distinct mass of about 50 g
Purity
Loss on drying Not more than 2.0% (105°C, 1 h)
Toluene-insoluble
matter
Not more than 0.3%
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The revisions of the existing EU specifications proposed by the panel are provided under
Section 3.5.
3.1.2.1. Analytical data from commercial samples of the food additive
3.1.2.1.1. Toxic elements
The call for data, requested:
• analytical data on current levels of lead, mercury, cadmium and arsenic in commercial samples
of the food additive,
• the lowest technologically achievable level for lead, mercury, cadmium and arsenic in order to
adequately define their maximum limits in the specifications.
Analytical data were provided by one interested business operator (documentation provided to
EFSA n.1) for levels of lead, mercury, cadmium and arsenic in samples of lecithins (E 322). The data
provided gives ranges only, said to be based on the analysis of more than 100 samples of different
types of lecithins. The sample types (source of the lecithins) were not specified. A variety of analytical
methods had been used and the limit of detection (LOD) and limit of quantification (LOQ) values differ
even for the same element. It seems possible that different test laboratories had been used at
different times, using different methods and equipment with different performance characteristics. Acid
digestion followed by ICP-MS gave the lowest LOD/LOQ values for Pb, Cd and As, but the specialised
method of combustion-amalgamation-cold vapour-AAS gave the lowest LOD/LOQ values for Hg.
For lead, the range of values was < 0.05–0.12 mg/kg. For mercury, the range of values was
0.0017 – < 0.02 mg/kg. For cadmium, the range of values was < 0.01–0.12 mg/kg. For arsenic, the
range of values was < 0.1–0.11 mg/kg. Since only the ranges were provided, the submitted data do not
give information as to the distribution of results, how many samples were non-detects etc. Although the
data reporting is limited, it was noted that the analytical methods used for toxic elements are up-to-date
and they were presented in a summarised way (usually including a reference to the Standard or Norm
used for sample preparation and for analytical determination) that is acceptable.
This interested business operator stated that ‘the lowest technically achievable level for a trace
metal element depends mainly on the levels that are achievable for the raw materials used. During the
manufacturing of lecithins there are no specific processes that are designed to reduce heavy metal
levels. Therefore, a reasonable specification that can be met with a high level of confidence for
standard food grade lecithin has to reflect what can be achieved routinely for all lecithins independent
of the raw material used’. The interested business operator indicated the values in Table 2 as the
lowest achievable levels of lead, mercury, cadmium and arsenic in lecithins are safe and suitable levels
for lecithin used in foods for all population groups including infants.
The Panel noted that based on the results from more than 100 samples (see above), the lowest
achievable levels proposed by the interested business operator in Table 2 are multiples of the highest
values reported: Pb is four times (0.5 vs 0.12), Hg is 294 times (0.5 vs 0.0017), Cd is two times
Commission Regulation (EU) No 231/2012
Acid value Lecithins: not more than 35 mg of potassium hydroxide per gram Hydrolysed lecithins:
not more than 45 mg of potassium hydroxide per gram
Peroxide value Equal to or less than 10
Arsenic Not more than 3 mg/kg
Lead Not more than 2 mg/kg
Mercury Not more than 1 mg/kg
Table 2: Lowest achievable levels of the toxic elements Pb, Hg, Cd and As for lecithins (E 322), as
proposed by one interested business operator for all population groups, including infants
below 16 weeks of age, independently of the raw material used as source (documentation
provided to EFSA n. 1)
Pb Hg Cd As
0.5 mg/kg 0.5 mg/kg 0.25 mg/kg 1 mg/kg
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(0.25 vs 0.12) and As is nine times higher (1 vs 0.11). Whereas allowance for some ‘headroom’ is to be
expected, the value proposed for Hg seems very much out of line with the reported results. The proposed
values would only be a modest improvement on the current EU specifications which are Pb = 2, Hg = 1
and As = 3 mg/kg. Currently for Cd, there is no limit in the EU specifications.
3.1.2.1.2. Residual protein
The call for data, requested:
• analytical data on current levels of residual proteins in commercial samples of the food
additive,
• the lowest technologically achievable level for residual proteins to reduce their content as
much as possible in view of case reports on hypersensitivity reactions associated with soya and
egg lecithins.
Information was received from one interested business operator (documentation provided to EFSA
n. 1). They stated that the residual protein content in lecithins (E 322) is defined by the amount of
toluene-insoluble (TI) or hexane-insoluble (HI) matter. The presence of this insoluble matter is
indicative of the presence of residual impurities such as protein and carbohydrate-containing extraction
residues and mechanical contaminants. Since for E 322, the EU specifications are no more than 0.3%
of toluene-insoluble matter, then this limits the possible protein content to a maximum of 0.3%. The
interested business operator further stated that according to EU legislation, protein content is analysed
as total nitrogen (Kjeldahl method) and since lecithins (E 322) contain non-protein nitrogen in its
phospholipid group, this analysis determines a value which will always be higher than the actual level
of protein-bound nitrogen present in lecithins (E 322). There is no recognised quantifiable routine
analytical method for analysing protein, as such, in lecithins. The interested business operator
concluded that TI or HI matter is the most appropriate parameter for ensuring a low, maximum level
of residual protein in lecithin and a limit of 0.3% is the level that is currently achievable.
The Panel noted that no analytical data were provided by the interested business operator on the
levels of toluene-insoluble matter, nor on the measurement of total nitrogen in commercial samples of
E 322. Notwithstanding that both approaches would tend to overestimate the protein content, such
information could be of use. In the absence of data, the Panel assumes that protein could be as high
at 0.3% w/w in E 322. It is noted that in the EFSA re-evaluation of lecithins (E 322) information on
protein content were provided by an interested business operator (EFSA ANS Panel, 2017). The
Panel noted that the source of lecithins e.g. egg, soya may contain proteins that can be responsible for
food allergy (EFSA NDA Panel, 2014).
3.1.2.1.3. Choline
The call for data, requested:
• information on the percentage of phosphatidylcholine content (mass %) in specific lecithins
preparations used as food additive E 322 in the infant formulae for infants below 16 weeks of
age (FC 13.1.1), as well as in special formulae for infants of that age under special medical
conditions (FC 13.1.5.1).
One interested business operator provided following background information, regarding total
choline (documentation provided to EFSA n. 2).
Total choline levels in infant formulae for infants below 16 weeks of age and in special formulae for
infants of that age under special medical conditions, as indicated on product labels (mg/100 mL) are
summarised below in Table 3. The total choline content relates to the level present in the final product
(as required to Article 7 of Commission Delegated Regulation (EU) No 2016/127) and corresponds to
choline from all potential sources, i.e. lecithins, choline added as a nutrient (e.g. free choline or choline
salts), and choline from natural sources (e.g. raw materials). As regulatory requirements for choline
are expressed on an energy basis, total choline content was also calculated on a mg/100 kcal basis
based on the energy content (kcal/100 mL) of the respective infant formula. Total choline levels in
infant formulae for infants below 16 weeks of age and in special formulae for infants of that age under
special medical conditions containing lecithins ranges from 13 to 26 mg/100 mL (25–39 mg/100 kcal).
These levels are in accordance with the compositional requirements for choline in infant formula of
25–50 mg/100 kcal, as per Commission Delegated Regulation (EU) 2016/127.
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The choline levels provided in Table 3 correspond to the level declared on the label of the products
placed on the EU market (documentation provided to EFSA n. 2,3).
On the question of the choline content in the E 322 used, one interested business operator
(documentation provided to EFSA n. 2,3) provided the following commentary and data on the
phospholipid composition of lecithins used in infant formulae for infants below 16 weeks of age and in
special formulae for infants of that age under special medical conditions.
The same interested business operator stated that soya lecithins liquid used in infant formulae for
infants below 16 weeks of age and in special formulae for infants of that age under special medical
conditions contains approximately 41–51% total phospholipids, and its phospholipid composition is
similar to that of commercial soya lecithins liquid for use as a food additive in all foods reported by the
European Lecithin Manufacturers Association (ELMA), previously evaluated by EFSA (EFSA ANS Panel,
2017; Table 2). Specifically, the phosphatidylcholine content of soya lecithins liquid used in infant
formulae for infants below 16 weeks of age and in special formulae for infants of that age under
special medical conditions is reported to range between 11.0% and 16.0% (see Table 4), whereas
phosphatidylcholine levels for this type of lecithins were previously reported to range between 12.7%
and 16.7% (EFSA ANS Panel, 2017; Table 2). Assuming the content of choline that can be theoretically
released from phosphatidylcholine containing two linoleate groups is 13.2% (EFSA ANS Panel, 2017),
up to 2.1% choline (i.e. 13.2% of 16.0% w/w) can be theoretically released from the amount of soya
lecithins liquid used in infant formulae for infants below 16 weeks of age and in special formulae for
infants of that age under special medical conditions.
Further, the interested business operator stated that sunflower lecithin liquid used in infant
formulae for infants below 16 weeks of age contains approximately 40–48% total phospholipids, and
also has a similar phospholipid composition to commercial sunflower lecithin liquid as considered by
EFSA previously. Specifically, the phosphatidylcholine content of sunflower lecithins liquid used in infant
formulae for infants below 16 weeks of age is reported to range between 14.8 and 18.2% (see
Table 4), whereas phosphatidylcholine levels for this type of lecithin were previously reported to range
between 14.3 and 17.2% (EFSA ANS Panel, 2017; Table 2). As a result, up to 2.4% choline (i.e.
13.2% of 18.2% w/w) can be theoretically released from the amount of sunflower lecithin liquid used
in infant formulae for infants below 16 weeks of age.
Table 3: Total choline in infant formulae for infants below 16 weeks of age and in food for special
formulae for infants of that age under special medical conditions as identified on the









Infant formulae for infants below
16 weeks of age
Soya lecithins liquid 130–260 25–39
Sunflower lecithins liquid 260 39
Infant formulae for infants below
16 weeks of age under special medical
conditions
Soya lecithins liquid 220 33
*: Calculated as: Total choline in mg/100 kcal = [(100 kcal)/ (9 kcal/100 mL) 9 (9 mg choline/100 mL)].
Table 4: Phospholipids composition of lecithins (E 322) used in infant formulae for infants below 16
weeks of age and in food for special formulae for infants of that age under special medical
conditions as identified on the product labels (documentation provided to EFSA n. 2)
Type of lecithins Total PL % PC % PI % PE % PA %
Infant formulae for infants
below 16 weeks of age
Soya lecithins liquid 41.1–50.6 11.0–16.0 8.0–12.6 7.5–14.0 2.0–7.0
Sunflower lecithins
liquid
39.7–47.5 14.8–18.2 12.0–15.6 5.4–8.1 1.7–4.6
Infant formulae for infants
below 16 weeks of age under
special medical conditions
Soya lecithins liquid 41.1–50.6 11.0–16.0 8.0–12.6 7.5–14.0 2.0–6.0
PA: phosphatidic acid; PC: phosphatidylcholine; PE: phosphatidylethanolamine; PI: phosphatidylinositol; PL: phospholipids.
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This information was found to be satisfactory and was considered under Section 3.6.2.5 with
respect to the possible contribution to choline intake in the diet.
3.1.2.1.4. Cronobacter (Enterobacter) sakazakii in the food additive
The call for data requested:
• data should be provided for foods for infants below 16 weeks of age demonstrating the
absence of Cronobacter (Enterobacter) sakazakii in the food additive.
One interested business operator provided information on tests for Cronobacter (Enterobacter)
sakazakii in lecithins used in infant formulae for infants below 16 weeks of age and in special formulae
for infants of that age under special medical conditions (documentation provided to EFSA n.2). The
samples were tested according to ISO 22964:2017 (ISO, 2017) using a quantitative real-time polymerase
chain reaction (qPCR) method. Cronobacter (Enterobacter) sakazakii was absent in five non-consecutive
lots of soya lecithins liquid, where the test result for each of the five samples was recorded as ‘Absent in
180 g’. Cronobacter (Enterobacter) sakazakii was also absent in five non-consecutive lots of sunflower
lecithin liquid, where the test result for each of the five samples was recorded as ‘Absent in 10 g’.
The Panel noted that in a publication on an inter-lab trial of the ISO 22964:2017 method (De
Benito et al., 2018), the sensitivity value, expressed as LOD-50 corresponding to the level of detection
for which 50% of tests give a positive result was calculated for three food items (two powdered infant
formulas and one starch) with values between 0.8 and 1.1 colony-forming unit (CFU)/sample. This
sensitivity is adequate.
The Panel noted the limited number of E 322 samples reported by the interested business operator
(five non-consecutive lots).
3.1.3. Information on particular specifications in the additive for use in infant
formulae
The interested business operator proposed specifications for lecithins (E 322) used in infant
formulae for infants below 16 weeks of age and in special formulae for infants of that age under
special medical conditions and compared and contrasted them with the specifications for lecithins
(E 322) laid out in Commission Regulation (EU) No 231/2012 of 9 March 2012 (Table 5).
The same interested business operator proposed lower maximum limits for As, Hg and Pb than the
existing EU specifications and than those proposed in Table 2. The justification for this distinction was
the differences in the sources of lecithins used; only sunflower and soya in the case of use in food for
infants below 16 weeks of age (see Tables 2 and 5). In a clarification follow-up (documentation
provided to EFSA n. 4), that business operator confirmed that their members are currently using only
soya and sunflower lecithins for E 322 intended for infants below 16 weeks of age but stated that they
could not speak for the whole industry.
Table 5: EU specifications and proposed revisions by the interested business operator for lecithins
(E 322) used in infant formulae for infants below 16 weeks of age and in special formulae for





Infant formulae for infants below 16
weeks of age
Special formulae for







Assay Not less than 60%
of substance
insoluble in acetone
Not less than 60% of
substance insoluble in
acetone
Not less than 60% of
substance insoluble in
acetone
Not less than 60% of
substance insoluble in
acetone










Opinion on the re-evaluation of lecithins (E 322)
www.efsa.europa.eu/efsajournal 15 EFSA Journal 2020;18(11):6266
The Panel noted that different specifications are proposed for lecithins from soya and sunflower.
They differ slightly on ‘loss on drying’, ‘acid value’ and ‘peroxide value’. The specifications proposed for
soya lecithins used for ‘normal’ formulae and ‘formulae for special medical conditions’ are the same
except a small difference in ‘description’ where ‘tan to amber liquid’ appears only once. This is of no
consequence. The specifications proposed for As, Pb and Hg are 15, 8 and 10 times lower than the
Regulation limit values. No specification is proposed for Cd. The specifications proposed for As, Pb and
Hg are lower than the ‘Lowest achievable levels’ stated (for all E 322 uses) above (Section 3.1.2.1.1).
This could be due to the fact that in Table 5, the focus is on lecithins from soya and sunflower
whereas in Section 3.1.2.1.1, the values were put forward for lecithins from all sources.
Regarding other possible contaminants, the interested business operator made the observation
that, in addition to specifications laid out in Commission Regulation (EU) No 231/2012 for lecithins,
additional contaminants and toxic elements (e.g. mycotoxins, persistent organic pollutants, pesticides
etc.) are controlled for in finished products for infants and young children by various regulations. The
maximum levels established for finished products take into consideration all potential sources of these
substances, including all additives and ingredients.
3.1.4. Stability of the substance and reaction and fate in food
The call for data, requested:
• information on the fate and the reaction products of lecithins (E 322) in the infant formulae for
infants below 16 weeks of age, as well as in special formulae for infants of that age under
special medical conditions.
One interested business operator stated that: ‘Lecithins are a mixture of acetone-insoluble
phosphatides (primarily phosphatidylcholine), combined with various amounts of other substances such





Infant formulae for infants below 16
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Passes test13 Passes test13 Passes test13 Passes test13
Test for choline Passes test13 Passes test13 Passes test13 Passes test13
Test for fatty acids Passes test13 Passes test13 Passes test13 Passes test13
Purity
Loss on drying Not more than
2.0% (105°C, 1 h)





Not more than 0.3% Not more than 0.3% Not more than 0.3%
Acid value Not more than 35
mg KOH/g
Not more than 30 mg
KOH/g
Not more than 35 mg
KOH/g
Not more than 30 mg
KOH/g
Peroxide value Not more than 10 Not more than 5 Not more than 10 Not more than 5
Heavy metals

























13 For description, see JECFA (2007a,b) as described also in EFSA ANS Panel (2017).
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manufacturing conditions of infant formulae for infants below 16 weeks of age and in special formulae
for infants of that age under special medical conditions. As a result, no significant change in
composition is expected during the manufacturing process. In the finished product matrix, the lecithin
ingredient itself is likely to dissociate into these individual components.’
The Panel noted that this is a viewpoint and no new information or data has been provided. There is also
only limited information on stability available in the EFSA ANS Panel opinion (2017) on E 322. The Panel finds
that the assumption is reasonable, that there are no concerns about stability of E 322 in infant formula.
3.2. Authorised uses and use levels
Maximum levels of lecithins (E 322) in foods for infants below 16 weeks of age are defined in
Regulation (EC) No 1333/2008 on food additives, as amended. In this opinion, these levels are termed
maximum permitted levels (MPLs).
According to Regulation (EC) No 1333/2008, Annex II, part E, lecithins (E 322) is authorised as a
food additive in infant formulae as defined by Commission Delegated Regulation (EU) 2016/127 (FC
13.1.1) and in dietary foods for infants for special medical purposes and special formulae for infants
(FC 13.1.5.1); and according to Regulation (EC) No 1333/2008, Annex III, part 5, section B, lecithins
(E 322) is authorised to be added as a food additive in (preparations of) all nutrients intended to be
used in foods for infants and young children, see Tables 6 and 7.
3.3. Exposure data
Some food additives are authorised in the EU in infants’ formulae as defined by Commission
Delegated Regulation (EU) 2016/127 (FC 13.1.1) and in dietary foods for infants for special medical
purposes and special formulae for infants (FC 13.1.5.1) at a specific MPL. However, a food additive
may be used at a lower level than the MPL. Therefore, actual use levels are required for performing a
more realistic exposure assessment.
In the framework of Regulation (EC) No 1333/2008 on food additives and of Commission
Regulation (EU) No 257/2010 regarding the re-evaluation of approved food additives, EFSA issued a
public call14 for technical and toxicological data on lecithins (E 322) as a food additive for uses in foods
for all population groups including infants below 16 weeks of age. In response to this public call,
Table 6: MPLs of lecithins (E 322) in foods for infants below 16 weeks of age according to Annex












13.1.1 Infant formulae as defined by Commission
Delegated Regulation (EU) 2016/127
E 322 1,000(a)
13.1.5.1 Dietary foods for infants for special medical
purposes and special formulae for infants
E 322 1,000(a)
(a): If more than one of the substances E 322, E 471, E 472c and E 473 are added to a foodstuff, the maximum level
established for that foodstuff for each of those substances is lowered with that relative part as is present of the other
substances together in that foodstuff.
Table 7: MPLs of lecithins (E 322) in foods for infants below 16 weeks of age according to Annex









E 322 Lecithins For uses in nutrient preparations under
the condition that the maximum level in
foods mentioned in point 13.1 of Part E
of Annex II is not exceeded
All nutrients Foods for infants
and young
children
14 Call for technical and toxicological data on lecithins (E 322) for uses as a food additive in foods for all population groups
including infants below 16 weeks of age. Available online: http://www.efsa.europa.eu/sites/default/files/consultation/callsforda
ta/180718_lecithins_0.pdf
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information on the actual use levels of lecithins (E 322) in infant formulae for infants below 16 weeks
of age (FC 13.1.1) and in special formulae for infants of that age under special medical conditions (FC
13.1.5.1) was made available to EFSA by the interested business operators. No analytical data on the
concentration of lecithins (E 322) those foods were made available by the Member States.
3.3.1. Reported use levels in food categories 13.1.1 and 13.1.5.1 according to
Annex II
The interested business operators provided EFSA with use levels (n = 20) of lecithins (E 322) used in
FC 13.1.1 and FC 13.1.5.1 (documentation provided to EFSA n. 2 and 3). For infant formulae as defined
by Commission Delegated Regulation (EU) 2016/127 (FC 13.1.1), typical and maximum levels (n = 16;
15 soya lecithins type and one sunflower lecithin type) ranged between 129 and 1,000 mg/L. For dietary
foods for infants for special medical purposes and special formulae for infants (FC 13.1.5.1), typical and
maximum levels (n = 4, all soya lecithins type) ranged between 652 and 990 mg/L.
3.3.2. Summarised data extracted from the Mintel’s Global New Products
Database
The Mintel’s GNPD is an online database which monitors new introductions of packaged goods in the
market worldwide. It contains information of over 3 million food and beverage products of which more than
1,100,000 are or have been available on the European food market. Mintel started covering EU’s food markets
in 1996, currently having 24 out of its 27member countries, Norway and UK presented in theMintel GNPD.15
For the purpose of this Scientific Opinion, Mintel’s GNPD16 was used for checking the labelling of
food and beverage products and food supplements for lecithins (E 322) within the EU’s food market as
the database contains the compulsory ingredient information on the label.
According to Mintel’s GNPD, lecithins (E 322) was labelled on 229 baby food products (i.e. baby
formulae for infants between 0 and 6 months) between January 2015 and June 2020. This represents
65% out of the total number of baby food products in the GNPD database during the same period of time.
3.4. Exposure estimates for infants below 16 weeks
Exposure to lecithins (E 322) from its uses as a food additive in formulae for infants below 16
weeks was estimated. This scenario is based on the recommended consumption levels from SC
Guidance (EFSA Scientific Committee, 2017). This guidance ‘recommends values of 200 and 260 mL
[formula]17 /kg bw per day as conservative mean and high level consumption values to be used for
performing the risk assessments of substances which do not accumulate in the body present in food
intended for infants below 16 weeks of age’. These recommended consumption levels correspond to
14- to 27-day-old infants consumption.
3.4.1. Dietary exposure to lecithins (E 322) from infant formulae
Table 8 summarises the estimated exposure to lecithins (E 322) from its use as a food additive both
in FC 13.1.1 and FC 13.1.5.1 for infants below 16 weeks of age.
Table 8: Dietary exposure to lecithins (E 322) in foods for infants below 16 weeks of age according
to Annex II, Part E to Regulation (EC) No 1333/2008 (in mg/kg bw per day)
Infants (< 16 weeks of age)
Regulatory maximum level exposure assessment scenario (1,000 mg/kg)
• Mean consumption (200 mL/kg bw per day) 200
• High-level consumption (95th percentile, 260 mL/kg bw per day) 260
Refined estimated exposure assessment scenario
Scenario using maximum use level reported by industry (1,000 mg/kg) for both FC 13.1.1 and FC 13.1.5.1
• Mean consumption (200 mL/kg bw per day) 200
15 Missing Cyprus, Luxembourg and Malta.
16 http://www.gnpd.com/sinatra/home/ accessed on 16/6/2020.
17 The term ‘formula’ was added here.
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The refined estimated exposure assessment scenario using the maximum use level reported by
industry (the result is equal to the regulatory maximum level exposure assessment scenario) was used
in the assessment, the mean occurrence scenario is reported and indicates that there are products on
the market giving lower exposure levels.
3.4.2. Uncertainty analysis
In accordance with the guidance provided in the EFSA opinion related to uncertainties in dietary
exposure assessment (EFSA, 2007), the following sources of uncertainty have been considered and
summarised in Table 9.
Lecithins (E 322) is authorised in FC 13.1.1 and FC 13.1.5.1 according to Annex II, Part E to
Regulation (EC) No 1333/2008 and in foods for infants (FC 13.1) according to Annex III, Part 5,
Section B of the same Regulation (EC) No 1333/2008. For the regulatory maximum level exposure
assessment scenario an overestimation may result in some cases. However, based on the assumption
that carers of children would be brand loyal to an infant formula (FC 13.1.1) or infant formulae for
special medical purposes (FC 13.1.5.1), this exposure assessment scenario (Table 9) would in general
result in a reliable estimation of exposure.
It should be noted that the use according to Annex III to Regulation No 1333/2008 was taken into
account in the regulatory maximum level exposure assessment scenario. The maximum level
authorised according to the Annex III is ‘For uses in nutrient preparations under the condition that the
maximum level in foods mentioned in point 13.1 of Part E of Annex II is not exceeded’.
3.5. Proposed revision to existing EU Specifications for lecithins (E 322)
The Panel noted that the occurrence data submitted by the interested business operators are
substantially lower than the current limits in the EU specifications. The Panel considered that the
maximum limits in the EU specifications for toxic elements should be established based on actual levels
measured in the food additive. If the European Commission decides to revise the current limits in the
EU specifications, the estimates of toxic elements intake as described below could be considered.
One interested business operator provided lowest achievable levels for As, Cd, Hg and Pb for the
additive intended for use in food for the general population (including infants below 16 weeks of age;
documentation provided to EFSA n. 1), for the purpose of defining appropriate specifications. A second
Table 9: Qualitative evaluation of influence of uncertainties on the dietary exposure estimate
Sources of uncertainties Direction(a)
Consumption data: one reference point only to estimate exposure during the period of up to 16
weeks of age
+/–
Regulatory maximum level exposure assessment scenario:
– exposure calculations based on the MPL according to Annex II Part E to Regulation (EC)
No 1333/2008
+
Refined exposure assessment scenarios:
– exposure calculations based on the maximum levels (reported use from industry) +
– exposure calculations based on the mean levels (reported use from industry) +/–
(a): +, uncertainty with potential to cause overestimation of exposure; –, uncertainty with potential to cause underestimation of
exposure.
Infants (< 16 weeks of age)
• High-level consumption (95th percentile, 260 mL/kg bw per day) 260
Scenario using mean use level reported by industry (310 mg/kg) for FC 13.1.1
• Mean consumption (200 mL/kg bw per day) 62
• High-level consumption (95th percentile, 260 mL/kg bw per day) 81
Scenario using mean use level reported by industry (900 mg/kg) for FC 13.1.5.1
• Mean consumption (200 mL/kg bw per day) 180
• High-level consumption (95th percentile, 260 mL/kg bw per day) 234
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interested business operator proposed lower maximum limits for As, Hg and Pb for E 322 when used
in infant formulae for infants below 16 weeks of age and in special formulae for infants of that age
under special medical conditions (documentation provided to EFSA n. 2). The justification for this
distinction was the differences in the sources of lecithins used; only sunflower and soya in the case of
use in food for infants below 16 weeks of age (see Tables 2 and 5). In a clarification follow-up
(documentation provided to EFSA n. 4), that business operator confirmed that their members are
currently using only soya and sunflower lecithins for E 322 intended for infants below 16 weeks of age
but stated that they could not speak for the whole industry.
The Panel agreed to consider these proposed values as a starting point to characterise the risk of
exposure to toxic elements derived from the consumption of the food additive. The potential exposure
to these toxic elements can be calculated by:
• assuming that the contamination of the additive may be up to the lowest achievable levels (1
(As), 0.25 (Cd), 0.5 (Pb) and 0.5 (Hg) mg/kg), as proposed by an interested business operator
for all age groups (documentation provided to EFSA n. 1),
• assuming that the contamination of the additive may be up to the maximum limits (0.2 (As),
0.25 (Pb) and 0.1 (Hg) mg/kg), as proposed by another interested business operator for the
EU specifications for infants below 16 weeks of age (documentation provided to EFSA n. 2,4),
and then by calculation pro rata to the dietary exposure to the food additive itself for the two different
groups.
With regard to the dietary exposure to the food additive for infants below 16 weeks of age, the
Panel considered the refined estimated exposure assessment scenario based on maximum use levels
(95th percentile), at 260 mg/kg bw per day (see Table 8). For the general population, the exposure
resulting from the refined brand-loyal scenario (95th percentile) was highest for children aged 3–9
years, at 187 mg/kg bw per day (see EFSA ANS Panel, 2017).
The maximum limits for toxic elements referred to above could result in an exposure which can be
compared with the following reference points, or health-based guidance values (HBGVs), for the four toxic
elements: a BMDL01 of 0.3–8 lg/kg bw per day for arsenic (EFSA CONTAM Panel, 2009a,b), a total weekly
intake (TWI) of 2.5 lg/kg bw for cadmium (EFSA CONTAM Panel, 2009a,b), a BMDL01 of 0.5 lg/kg bw per
day for lead (EFSA CONTAM Panel, 2010) and a TWI of 4 lg/kg bw for mercury (EFSA CONTAM Panel,
2012).
The outcome of such an exercise (see Tables 10 and 11) illustrates the health impact that would
result if the proposed maximum limits for toxic elements were to be used.
Table 10: Risk assessment for toxic elements based on the lowest achievable levels in lecithins (E
322) for use in food for all age groups as proposed by an interested business operator




MOS/MOE for As MOS/MOE for Pb % of the TWI for Cd % of the TWI for Hg
1 mg/kg 0.5 mg/kg 0.25 mg/kg 0.5 mg/kg
187* 1.6–43 5.4 13% 16%
260 (see Table 8)** 1.2–31 3.9 18% 23%
*: Exposure to E 322 in children aged 3–9 years (refined, brand-loyal scenario, 95th percentile), the worst-case exposure
scenario for the population above 16 weeks of age (see EFSA ANS Panel, 2017).
**: Exposure to E 322 in infants below 16 weeks of age (high-level consumption, 95th percentile, 260 mL/kg bw per day).
Table 11: Risk assessment for toxic elements based on the maximum limits/lowest achievable levels




MOS/MOE for As MOS/MOE for Pb % of the TWI for Cd % of the TWI for Hg
0.2 mg/kg# 0.25 mg/kg# 0.25 mg/kg** 0.1 mg/kg#
260 (see Table 8)* 5.8–154 7.7 18% 5%
*: High-level consumption (95th percentile, 260 mL/kg bw per day).
**: According to the lowest achievable levels in lecithins (E 322) for use in food for all age groups as proposed by an interested
business operator (Documentation provided to EFSA n. 1), see Table 2.
#: Based on the maximum limits for toxic elements in lecithins (E 322) as proposed by an interested business operator using
only soya and sunflower as sources (Documentation provided to EFSA n. 2).
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The resulting figures show, in both exposure scenarios described, that the exposure to toxic
elements from the consumption of E 322 is substantial. The Panel noted that the MOS/MOE for arsenic
and lead is very low, considering that for lead, the reference point is based on perturbation of
intellectual development in children (who have the highest exposure), and for arsenic, the reference
point is based on carcinogenicity. It is further noted that the exposure to toxic elements from the
consumption of E 322 in infants below 16 weeks of age based on the existing EU specifications would
be even higher and would result in MOS/MOE of 0.38–10 for As and 0.96 for Pb and in % of the TWI of
46% for Hg. Similarly, for the remaining populations groups, the resulting MOS/MOE would be 0.53–14
for As and 1.34 for Pb and the resulting % of the TWI would be 33% for Hg. This supports the ANS
Panel recommendation to decrease the current maximum limits set for arsenic, lead and mercury,
considering also other sources of exposure to these toxic elements, and to introduce a maximum limit
for cadmium.
The Panel emphasises that setting the maximum limits for toxic elements in the specifications is in
the remit of risk management.
With regard to the levels of residual proteins in commercial samples of E322 (expressed as
percentage of toluene-insoluble matter), and the related lowest technologically achievable levels, no
analytical data were provided by the interested business operators. In the absence of data, the
Panel assumes that protein could be as high at 0.3% w/w as currently laid down in EU specifications
for E 322. The Panel considers that the existing EU specification on the levels of proteins should be
retained, i.e. percentage of toluene-insoluble matter. This is based on the data on post marketing
surveillance provided by the interested business operator (Documentation provided to EFSA n. 2,3)
showing rare cases of food allergy/intolerance-related symptoms.
On the basis of the information provided, the Panel consider that criteria should be included for
Cronobacter (Enterobacter) sakazakii.
Overall, based on the analytical data provided by the interested business operators in response to
EFSA call for data (footnote) (Documentation provided to EFSA n. 1 and 2) and the relative above
considerations, the Panel recommends the following revisions of the existing EU specifications for
Lecithins (E 322) as listed in Table 12.




Definition for brevity, see Table 1 Unchanged
Assay see Table 1 Unchanged
Description see Table 1 Unchanged
Identification see Table 1 Unchanged
Purity see Table 1 Unchanged
Loss on drying see Table 1 Unchanged
Toluene-insoluble
matter
see Table 1 Unchanged
Acid value see Table 1 Unchanged
Peroxide value see Table 1 Unchanged
Arsenic Not more than 3 mg/kg Lowered on the basis of the information provided and
based on the considerations of the panel
Lead Not more than 2 mg/kg Lowered on the basis of the information provided and
based on the considerations of the panel
Mercury Not more than 1 mg/kg Lowered on the basis of the information provided and
based on the considerations of the panel
Cadmium not presently specified To be included on the basis of the information provided





not presently specified Microbiological criteria should be included on the basis of
the information provided; Negative in 10 g
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3.6. Biological and Toxicological data
3.6.1. Previous evaluation by ANS Panel (2017)
The following text (in italics) is from the opinion published in 2017 (EFSA ANS Panel, 2017). New
information and assessments related to the specific age group below 16 weeks of age are added in the
following paragraphs.
Absorption, distribution, metabolism and excretion
Overall, studies using radiolabelled phosphatidylcholine in animals and humans clearly indicated that,
following oral administration, phosphatidylcholine is absorbed unchanged or as lysophosphatidylcholine
or choline after intestinal hydrolysis. In intestinal mucosa cells, lysophosphatidylcholine would be
reacylated into phosphatidylcholine or hydrolysed to glycerophosphocholine and free fatty acids. The
fatty acids would be further utilised for the reassembly of triacylglycerides and phosphatidylcholine found
in the chylomicrons. In humans, the absorbed phosphatidylcholine would be incorporated preferentially
into the HDL fraction of plasma. Peak levels of phosphatidylcholine in blood are reached within 6 h.
Besides the intestinal wall, the major target organ for distribution and metabolism of lecithins is the liver.
Only minor amounts of radioactivity were excreted via urine and faeces demonstrating that the
administered lecithins would undergo metabolism as for endogenous phospholipids. From the current
database, the Panel noted that only minor levels of choline labelling radioactivity were detected in the
brain. In humans, dietary lecithins are known to be hydrolysed by phospholipases to liberate choline, which
is rapidly absorbed by a carrier-mediated saturable transport system and appears in plasma predominantly
as free choline. Consequently, an increased plasma-free choline concentration has been described as a
consequence of increased dietary intake of lecithins. Moreover, a significant increase in breast milk
concentrations of free choline was observed in lactating women receiving a phosphatidylcholine
supplement in comparison with the placebo group.
Acute, subchronic, genotoxicity, chronic, developmental, reproductivity and neurotoxicity
studies
The acute toxicity of lecithins (E 322) in mice, rats and rabbits is low. The Panel noted that in these
studies the test substance is not always characterised.
Subchronic toxicity studies in rats and dogs did not report any adverse effect, even at the highest
doses tested (3,750 mg EPL (see Section 3.1.1)/kg bw per day, 1,000 mg soya phosphatidylinositol or
EPL18/kg bw per day in rats and dogs, respectively, and 5,460 mg lecithins/kg bw per day in rats).
The Panel considered the available genotoxicity data on lecithins (E 322) to be sufficient to
conclude that there is no concern with respect to genotoxicity.
Chronic toxicity studies in rats did not report any adverse effects, even at the highest dose tested
(3,750 mg EPL/kg bw per day). No carcinogenic effects were reported in rats, even at the highest
dose tested (1,470 and 2,280 mg soya lecithin/kg bw per day in males and females, respectively) for 2
years.
The Panel considered that no adverse effects were observed in the developmental toxicity studies
performed in mice, rat and rabbits up to the highest dose tested. However, the Panel noted that no
reproductive toxicity studies were available.
Against the background that choline availability as a precursor of acetylcholine may possibly
influence neurotransmitter systems, several neurodevelopmental toxicity studies were conducted with
lecithin. The Panel noted that the neurodevelopmental toxicity studies of Gozzo et al. (1982) in mice
and the studies of Bell and co-workers in rats (Bell and Lundberg, 1985; Bell and Slotkin, 1985; Bell
et al., 1986) had several limitations, such as the number of pregnant animals, the number of litters,
and the sex of the pups in the control and treated groups not being described in sufficient detail. In
addition, the length of gestation and pup weight at birth, as well as during the tests, were not
presented in all publications. Therefore, the Panel concluded that the relevance of the studies is limited
but, at concentrations of 5% soya lecithin and higher in the diet during the gestation, lactation and the
post-weaning period, there were indications for alterations in the development of the brain.
18 essential phospholipid.
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3.6.2. Newly available data
3.6.2.1. Absorption, distribution, metabolism and excretion
No new data were submitted by the interested business operators or found in the provided
literature search (documentation provided to EFSA n. 1 and 2).
The Panel considered that the physiological processes involved in absorption, distribution,
metabolism and excretion of lecithins described in the opinion published in 2017 (EFSA ANS Panel,
2017) are relevant also for infants below 16 weeks of age.
3.6.2.2. Toxicological data
None of the studies identified in the literature by the Panel and submitted by the interested
business operators aimed to investigate toxicity of lecithins as food additive (E 322) in juvenile
animals. The studies did not follow any specific OECD test guideline and were not performed according
to the good laboratory practice (GLP) principles.
Effects of soya lecithins during the pre- and post-natal period
A study evaluating effect of diet supplementation with soya lecithins on growth and reproductive
performance during summer and winter was conducted in rabbits (Attia et al., 2018). FV-line female
rabbits (6 months old, nulliparous at the start of the study; n=10/group) were kept on a pelleted diet
added 0% (control), 0.5%, 1% or 1.5% soya lecithins (equivalent to 0 and approximately 150, 300 or
450 mg/kg bw per day;) starting one month before mating until day 35 of the third lactation. The
does were mated three times during each season (summer or winter) with males kept on the control
diet. Pregnancy was checked on day 10 after pairing. Non-pregnant does were mated until pregnancy
was achieved. Body weight of does was recorded immediately after mating and after parturition. Feed
intake was measured from mating up to the end of the first week after parturition (5 weeks), in each
of pregnancy periods. Milk production was measured from birth to the 35th day after parturition.
Reproductive performance was evaluated by receptivity rate, conception rate and the number of
matings required to induce pregnancy at the 10th day after mating. Live litter size and pup weight at
birth and at 35 days of age were reported. No does died during the study. Body weight of does on diet
added 1% or 1.5% soya lecithins was statistically significantly higher and daily feed intake statistically
significantly lower than in the controls. In comparison to the group on the control diet, milk production
was statistically significantly higher in groups receiving diets with 1% and 1.5% soya lecithins at all
time points measured. Receptivity and conception rates were statistically significantly higher for does
on diet added 1% or 1.5% soya lecithins as compared with controls. The number of matings was
similar in all groups fed the soya lecithins added diets and was statistically significantly lower than in
the controls. The litter sizes at birth and at the weaning were statistically significantly greater in all
soya lecithins dietary groups than in the control group. At the same time, the litter sizes were similar
for 1% or 1.5% soya lecithins dietary groups being statistically significantly greater than in 0.5% soya
lecithin dietary group. Statistically significantly higher than in controls pup body weights were recorded
for all soya lecithins dietary groups at birth (+8%, +15% and +15% for 0.5, 1 and 1.5% SL groups,
respectively) and for 1% (+7%) and 1.5% (+8%) soya lecithins dietary groups at the end of weaning.
The Panel noted that these findings have no toxicological relevance. The interaction of soya lecithins
addition to the diet with a season influenced the size of the offspring at birth and at weaning for 1%
and 1.5% soya lecithins in the diet. There was no effect of interaction between soya lecithins addition
to the diet and the season on body weight and feed intake of does but a statistically significant effect
was recorded for the size of offspring at birth and at weaning, and on composition of milk regarding
the content of saturated and unsaturated fatty acids. The Panel considered that dietary doses up to
1.5% soya lecithins (equivalent to 450 mg/kg bw per day) had no adverse effect on body weight and
survival of does, milk production on reproductive indices (receptivity and conception rates and number
of services), litter size and pup weights.
A study evaluating effect of soya lecithins and similar products on reproductive performance was
performed in pregnant sows (Cao et al., 2018). Pregnant binary hybrid sows (approximately 30 in each
group, body weight not reported) were fed basal diet (control) or received 50 g/animal per day of soya
lecithins or two other products in basal diet (twice a day 25 g) from day 100 of gestation until day 7 after
birth. Daily feed intake of sows from soya lecithins group (3.64 kg  0.03) was slightly but statistically
significantly increased compared to that in the controls (3.54 kg 0.03). The following reproductive
indices were statistically significantly higher in the soya lecithins group as compared to the controls: the
litter size (11. 31  0.23 vs 10.69  0.27), life litter size (10.71  0.22 vs. 10.00  0.26) and qualified
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litter size (piglets with birth weight greater than 0.8 kg) (10.32  0.22 vs. 9.56  0.26). Piglet birth
weight in soya lecithins (1.48 kg  0.02) and control (1.45 kg  0.02) groups was similar.
Another study in pregnant sows evaluated effects of soya lecithins (SL) on reproductive
performance, colostrum and milk composition and immunoglobulin levels in milk and plasma from
sows and offspring (Shi et al., 2019). Four groups of pregnant sows (crossbred Large
White 9 Landrace, n = 12/group) were fed for 28 days i.e. from the 107th day of gestation until day
21 of lactation (weaning) either a control diet with 3% soybean oil (SO, Habin Gushi A&H, digestive
energy 36.31 MJ/kg) (equivalent to 1,200 mg SO/kg bw per day) or the diets in which SO was
replaced by 1%, 2% or 3% SL (Habin Gushi A&H, digestive energy 306.29 MJ/kg) (equivalent to 400,
800 or 1,200 mg SL/kg bw per day). Replacements of SO with SL had no statistically significant effects
on body weight, body weight gain and mean daily feed intake of sows. Reproductive parameters like
number of piglets born/alive per litter, number of piglets at weaning per litter, survival rate of piglets,
piglet weight at birth were comparable between all four groups. The body weights and mean body
weight gain of piglets at weaning were statistically significantly higher (+16 and +20%, respectively) in
3% SL group compared with the control group (3% SO). The composition of colostrum and milk with
regard to the content of lactose, fat, protein and total solids was comparable between all groups, but
statistically significant differences with the control group were recorded in immunoglobulin
concentrations. In colostrum, IgA was higher in all SL groups and IgM in 2% and 3% SL groups. In
milk, IgA was higher in 3% SL group. Content of phosphatidylcholine and total phospholipids was
statistically significantly higher and fat globules were smaller in milk from 2% and 3% SL groups
compared with the control group. The addition of SL did not produce toxicologically relevant changes
in the plasma levels of immunoglobulins in sows and piglets. The Panel noted that this study provides
limited evidence that lecithins as food additive have no adverse effects on the parameters measured in
the piglets.
Effects of egg lecithins on immunological parameters
A study investigating effects of egg lecithins (PC, lipid-soluble phosphatidylcholine, egg lecithins; no
further data on the origin of the tested lecithins were provided) and free choline (FC, choline
bitartrate) in the maternal diet on the development of the offspring’s immune system was performed
in rats (Lewis et al., 2016). Pregnant Sprague-Dawley dams (n = 10) were kept on a standard diet
from the 14th gestation day until 14–48 h after parturition. Thereafter, the dams were divided in two
groups (five in each) and fed ad libitum either a diet containing PC or FC. Both diets provided 1 g/kg
diet (0.1%; equivalent to 50 mg/kg bw per day) of total choline and had a similar fat content (wt/wt
%) and fatty acid composition. The litter size was standardised at birth to 10 pups (five males and five
females when possible) per dam. At weaning (day 21), two pups (sex not described) from each litter
were weighed, killed (CO2 asphyxiation), liver and spleen were weighed, splenocytes harvested.
Stomach content, liver, splenocytes and plasma were used to measure their choline concentration.
Immune cell subsets in splenocytes were identified. Cytokine concentration was measured in plasma.
Splenocytes were used for assays of ex vivo cytokine production after stimulation with concanavalin A
(ConA) or lipopolysaccharide (LPS). The daily feed intake of dams on the PC or FC diets during the
weaning was 40 g/animal. In pups from PC or FC dietary groups body and organ weights, intestinal
length, relative number of splenocytes (number of splenocytes per gram of spleen) and total choline
concentrations in the stomach or plasma were comparable. PC concentrations in plasma and spleen of
pups from PC fed dams were higher than in the pups from FC fed dams. In pups from the PC fed
dams as compared to pups from FC fed dams, the differences in splenocyte immune cell phenotype
included a statistically significantly lower proportion of total B cells (Ig+ cells, OX12+), proportion of
activated macrophages (CD68+CD11b/c+) and total cells expressing major histocompatibility complex
class II (OX6+). In the ex vivo assay splenocytes from pups of PC group produced 54% more
interleukin (IL)-2, 163% more IL-6 and 107% more IFN-c than splenocytes from pups of FC group
after ConA stimulation and 110% more IL-6 and 43% more TNF-a than those from pups of FC group
after stimulation with LPS. The large variations and the absence of a well-defined control group
preclude a clear conclusion on this study.
Effect of egg phospholipids and soya lecithins during post-natal period
Effect on general health of algal/fungal triglyceride oils (TG) or egg phospholipids (PL) as sources of
long-chain polyunsaturated fatty acids was investigated in piglets when administered from postnatal
day (PND) 1–16 (Mathews et al., 2002). One-day-old piglets (no information on strain or sex) from 13
sows were assigned to one of the following dietary treatment groups:
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1) piglet formula without arachidonic acid (AA) or docosahexaenoic acid (DHA (control, n = 10),
2) piglet formula from egg phospholipids (PL, n = 10, 85 g/kg formula),
3) piglet formula from the fungal and algal triglyceride oils (TG, n = 10),
4) piglet formula from the fungal and algal triglyceride oils with additional choline (10.6 g/kg
formula), cholesterol (4.5 g/kg) and soya lecithins (34 g/kg)) (TG + PL, n = 10) to match
the PL formula,
5) piglet formula deficient in essential fatty acids (EFA) (EFAD, n = 8). An additional control
consisted of 13 sow-reared piglets from two litters (a natural fed control).
According to the authors, the control, PL, TG and TG + PL formulas contained adequate amounts of
linoleic (LA) and a-linolenic (LN) acids. PL, TG and TG + PL formulas contained AA and DHA in the
same amounts.
Body weight, body weight gain, daily feed intake, feed efficiency, ALT, BUN and cholesterol plasma
levels, liver weight or vacuolation of cytoplasm in hepatocytes did not differ between the control
formula, PL, TG and TG + PL groups. In PL group, aspartate aminotransferase (AST) was statistically
significantly higher than in TG + PL group (being comparable to that in the control formula and TG
groups) and plasma glucose concentration was statistically significantly lower than in the control
formula, TG, TG + PL groups. The PL group had a lower ileal apparent dry matter digestibility in
comparison to the control formula or TG groups. Jejunal or ileal lactase specific activity was
comparable between control formula, PL, TG, TG + PL groups. Jejunal villi height was comparable
between control formula, PL, TG, TG + PL groups, but ileal villi height in PL group was lower than in
the control formula group. Jejunal and ileal villi width and crypt depth were comparable between
control formula PL, TG, TG + PL groups. Apparent dry matter digestibility was 10% greater in controls,
TG and TG + PL groups compared with PL piglets. The Panel considered that this study did not show
toxicologically relevant effects on growth, feed intake and feed efficiency, clinical chemistry, liver
weight or lipid and glycogen accumulation in piglets fed with formulae containing powdered soya
lecithins (no estimate for the lecithins intake in mg/kg bw per day can be made) compared to feeding
a control formula.
3.6.2.3. Clinical data
No clinical studies relevant for the safety evaluation of lecithins (E 322) in infants below 16 weeks
were submitted by interested business operators or found in a literature search.
3.6.2.4. Post-marketing surveillance data
Post-marketing data were obtained from one interested business operator in the form of a
summary table of adverse events of two different companies (documentation provided to EFSA n. 2
and 3). The first company provided data collected between November 1, 2017 and October 31, 2019
on lecithin-containing formula products available on the market in the United States, during which
period several millions of individual items were sold. From 450 reported adverse events, the terms
most often mentioned were gas (178 events), spitting up (119 events), fussy (106 events), crying (52
events), vomiting (41 events), constipation (39 events), refused (34 events), stomach upset (32
events), diarrhoea (30 events) and discomfort (24 events). The second company provided data
collected in 2016 and 2017 on lecithin-containing products. Among several millions of individual items
sold, between the 44 adverse events reported, 39 were described as ‘unspecific nutritional disorders
(e.g. diarrhoea, vomiting, obstipation)’ and 5 as ‘allergic reaction/intolerance’.
The Panel considered that the relationship between the events and the intake of lecithins (E 322) is
not confirmed and that the post-marketing surveillance data do not show specific alerts except for the
very rare symptoms of ‘allergic reaction/intolerance’.
3.6.2.5. Comparative data on the content of lecithins in human milk and in infant formula
Total Phospholipids in maternal milk
The interested business operators collected several studies reporting on maternal milk levels of total
phospholipids in mg/L (Hibberd et al., 1982; Bitman et al., 1986; Sala-Vila et al., 2005; Garcia et al.,
2011, 2012; Giuffrida et al., 2013; Thakkar et al., 2013; Ma et al., 2017; Cheong et al., 2018; Jiang
et al., 2018; Ingvordsen Lindahl et al., 2019; McJarrow et al., 2019; Wei et al., 2019; Wu et al., 2019;
documentation provided to EFSA n. 2 and 3).
The studies were performed in various countries (China, France, Germany, Ireland, Malaysia,
Singapore, Spain, United Arab Emirates, the U.S. and the UK) and the participating women were not a
Opinion on the re-evaluation of lecithins (E 322)
www.efsa.europa.eu/efsajournal 25 EFSA Journal 2020;18(11):6266
random selection of the population of those countries. Because of various factors, the data are
heterogeneous and variable (influence of diet on milk composition; Ballard and Morrow, 2013). Various
analytical methods were used for separation and quantification introducing variability.
From the original study results, the interested business operators calculated 1) the average of the
reported means; 2) the maximum reported mean level; 3) median levels; and 4) the maximum
reported level (documentation provided to EFSA n. 3). The interested business operators presented
data on colostrum, transitional milk and mature milk; however, this assessment focused on mature
milk. These values are presented in Appendix B.
Phospholipids and choline levels in infant formulae
According to data provided by SNE members and confirmed by ELMA, lecithins (E 322) used in
infant formulae for infants below 16 weeks of age and in special formulae for infants of that age under
special medical conditions are composed of 39.7–50.6% total phospholipids, see Appendix B
(documentation provided to EFSA n. 2 and 3).
Choline levels in maternal milk
Mean concentration and SD of choline in maternal milk were also calculated based on the data
from the literature (Documentation provided to EFSA n. 3), see Appendix B.
Contents of phospholipids and choline in human milk and in formula
The content of phospholipids was calculated from the lecithins content in the formula, using the
data given in Table 4 (see Table 13). The levels of phospholipids in the formula and the level of total
phospholipids in mature milk are not directly comparable. The Panel focused on the comparison of the
total choline.
Comparison of the levels of choline in human milk and in infant formula
When comparing the total choline content of formula with that of human milk a difference is
observed. Nearly 75% of the total choline in the formula is added as nutrient whereas only around 5%
of total choline are present due to release from lecithins (E 322) and additional 22% from other
ingredient sources (Table 13).
3.7. Discussion
The Panel considered it feasible to amend the EU specifications based on the information submitted
in response to the call for data. This refers to lowering existing limits for toxic elements, as well as
introducing new specifications for cadmium and microbiological criteria for the food additive (see
Table 12).
No new data on absorption, distribution, metabolism and excretion of lecithins were submitted by
the interested business operators or found in a literature search. The Panel considered that the
physiological processes involved in absorption, distribution, metabolism and excretion of lecithins
described in the opinion published in 2017 (EFSA ANS Panel, 2017) are present and taking place also
in infants below 16 weeks of age.
In the re-evaluation of lecithins (EFSA ANS Panel, 2017), the acute toxicity of lecithins (E 322) in
mice, rats and rabbits was considered as low. In addition, ANS Panel concluded that subchronic






Total phospholipids mg/L 248  91# 239.7  216.7* 202.3  182.9**
Total choline (mg/L) 138.3  15.9# 225  26#,***
Choline added as nutrient (mg/L) 166  37#
Choline from lecithins (mg/L) 12  8#
Choline from other ingredient
sources (mg/L)
50  17#
*: Calculated by the Panel from lecithins content in formula using a factor of 0.506 (see Table 4).
**: Calculated by the Panel from lecithins content in formula using a factor of 0.475 (see Table 4).
***: Includes choline added as nutrient, from lecithins and from other ingredients sources.
#: Calculated by the interested business operator (Documentation provide to EFSA n. 2, 3).
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toxicity studies in rats and dogs did not report any adverse effect, even at the highest doses tested
(3,750 mg EPL/kg bw per day, 1,000 mg soya phosphatidylinositol or EPL/kg bw per day in rats and
dogs, respectively, and 5,460 mg lecithins/kg bw per day in rats). The ANS Panel considered the
available genotoxicity data on lecithins (E 322) to be sufficient to conclude that there is no concern
with respect to genotoxicity. Chronic toxicity studies in rats did not report any adverse effects, even at
the highest dose tested (3,750 mg EPL/kg bw per day). No carcinogenic effects were reported in rats,
even at the highest dose tested (1,470 and 2,280 mg soya lecithins/kg bw per day in males and
females, respectively) for 2 years. The ANS Panel considered that no adverse effects were observed in
the developmental toxicity studies performed in mice, rat and rabbits up to the highest dose tested.
However, the ANS Panel noted that no reproductive toxicity studies were available.
The main safety concern identified in the EFSA Opinion (EFSA ANS Panel, 2017) regarded
indications for alterations in the development of the brain at concentrations of 5% soya lecithins and
higher in the diet during the gestation, lactation and the post-weaning period in the
neurodevelopmental toxicity studies of Gozzo et al. (1982) in mice and in the studies of Bell and co-
workers in rats (Bell and Lundberg, 1985; Bell and Slotkin, 1985; Bell et al., 1986). It has to be noted,
however, that these studies had limitations which precluded firm conclusions by the ANS Panel.
The newly provided studies (Attia et al., 2018; Cao et al., 2018; Shi et al., 2019; Lewis et al., 2016;
Mathews et al., 2002) did not contribute to the assessment of potential neurodevelopmental effects
because this endpoint has not been addressed in the studies. Specific studies in infants were not
provided and the data from the post-marketing surveillance studies do not allow to make firm
conclusions on the safety of lecithins (E 322) in infant formula.
For the reason that choline is a precursor of the neurotransmitter acetylcholine the ANS
Panel considered appropriate to address the safety of lecithins (E 322) as food additive in infant
formula used in infants below the age of 16 weeks by comparing the exposure by infant formula with
the adequate intake (AI) set by the EFSA NDA Panel (EFSA NDA Panel, 2016a). In following the
proposed approach, the FAF Panel considered that it is appropriate to compare the concentration of
choline in human milk with that in the formula, because the AI is based on the choline content of
human milk.
From the information provided by the interested business operator, the mean content of total
choline in formula (225 mg/L) is around 62% higher than that in human milk (138 mg/L). However,
the mean content of choline released from lecithins used as a food additive (E 322) in infant formula
(12 mg/L) represents only 8.7% of the mean content of total choline in mature human milk. The same
conclusion applies at the MPL of 1,000 mg/L for E 322, in accordance with Annex II, Part E to Reg
1333/2008, which could contribute to 21 mg/L of choline (see Section 3.1.2.1.3). Most (nearly 75%) of
the total choline content in infant formula is derived from the addition of choline as nutrient.
The minimum and maximum total content of choline in infant formula is regulated (Regulation
2016/127) at, respectively, 25 and 50 mg/100 kcal, i.e. around 175–350 mg/L. (assuming a maximum
energy content for infant formula of 700 kcal/L). Therefore, the mean content of choline released from
lecithins in infant formula represents only 6.9% and 3.4% (see Table 13) of the minimum and
maximum content of choline regulated in infant formula. The assessment of choline added as nutrient
is not in the remit of this Opinion.
According to Annex II, Part E of Regulation (EC) No 1333/20082, lecithins (E 322) are permitted in
food categories 13.1.1 ‘infant formulae’ and 13.1.5.1 ‘dietary foods for infants for special medical
purposes and special formulae’ (FSMP) for infants at a maximum level of 1,000 mg/L. Lecithins (E 322)
are also authorised as food additive in (preparations of) all nutrients intended to be used in foods for
infants and young children according to Annex III, Part 5, Section B of Regulation (EC) No 1333/2008
provided that the maximum level defined in Annex II, Part E is not exceeded.
Based on data submitted by SNE members, lecithins (E 322) are used in infant formulae for infants
below 16 weeks of age and in special formulae for infants of that age under special medical conditions
at levels of up to 1,000 mg/L, and are thus in compliance with maximum permitted levels in the EU.
For infants below 16 weeks of age consuming infant formulae (FC 13.1.1) or infant food for special
medical purpose (FSMP) (FC 13.1.5.1), in the regulatory maximum level exposure assessment
scenario, mean exposure to lecithins (E 322) was estimated to be 200 mg/kg bw per day while the
high level was estimated at 260 mg/kg bw per day. In the refined scenario, exposure was the same
using the maximum reported levels by the interested business operators (for both FC 13.1.1 and
13.1.5.1); while using the mean reported levels by the interested business operators, refined exposure
is estimated at 62 mg/kg bw per day at the mean (81 mg/kg bw per day at the p95) for FC 13.1.1
and at 180 mg/kg bw per day at the mean (234 mg/kg bw per day at the p95) for FC 13.1.5.1.
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4. Conclusions
Taking into account the data submitted by interested business operators and the considerations
from the Panel, a revision of the existing EU specifications for lecithins (E 322) has been recommended
(see Table 12).
The choline released from lecithins (E 322) is a minor contributor (around 8.7% as the mean) of
the total content of choline of the formula and does not raise concern at the current use levels
including the MPL for lecithins (E 322). Most of the choline in the formula is due to the choline added
as a nutrient. In addition, it can be stated that the mean content of choline is in the range of the
adequate intake level (AI). The Panel concluded that the intake of lecithins (E 322) as a food additive
in infant formula belonging to FC 13.1.1 or in food for special medical purposes belonging to FC
13.1.5.1 does not raise safety concerns up to the MPL of lecithins (E 322).
5. Recommendation
The Panel recommends the European Commission to consider revising the current specifications for
the food additive lecithins (E 322) on the basis of the information provided and based on the
considerations of the Panel, see Table 12.
6. Documentation as provided to EFSA
1) European Lecithin Manufacturers Association (ELMA), 2019. Submission of data in response
to the call for technical and toxicological data on lecithins (E 322) for uses as a food additive
in foods for all population groups including infants below 16 weeks of age. Submitted on
December 2019.
2) Specialised Nutrition Europe (SNE), 2019. Submission of data in response to the call for
technical and toxicological data on lecithins (E 322) for uses as a food additive in foods for
all population groups including infants below 16 weeks of age. Submitted on December
2019.
3) Specialised Nutrition Europe (SNE), 2020. Clarification on the data in response to the call for
technical and toxicological data on lecithins (E 322) for uses as a food additive in foods for
all population groups including infants below 16 weeks of age. Submitted on June 2020.
4) Specialised Nutrition Europe (SNE), 2020. Clarification on the data in response to the call for
technical and toxicological data on lecithins (E 322) for uses as a food additive in foods for
all population groups including infants below 16 weeks of age. Submitted on July 2020.
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Appendix A – Data requested in the call for data (call for technical and
toxicological data on lecithins (E 322) for uses as a food additive in foods
for all population groups including infants below 16 weeks of age19





A. Information regarding the follow-up of the conclusions and the recommendations of the EFSA
ANS Panel opinion on the safety of lecithins (E 322) as food additive
1.Technical data • analytical data on current levels of
lead, mercury, cadmium and
arsenic in commercial samples of
the food additive
• the lowest technologically
achievable level for lead, mercury,
cadmium and arsenic in order to
adequately define their maximum
limits in the specifications
• analytical data on current levels of
residual proteins in commercial
samples of the food additive
• the lowest technologically
achievable level for residual
proteins to reduce their content as
much as possible in view of case
reports on hypersensitivity




2.Toxicological data – – –
3. Literature
searches
Literature searches should be conducted
relevant for the safety evaluation of
lecithins (E 322) for all uses in foods for
all population groups from 23/11/2016 up
to the date of the data submission, as
described in the Guidance for submission




B. Information required for the risk assessment of lecithins (E 322) as food additive for use in
foods for infants below 16 weeks of age
1. Technical data • information on the levels of use of
lecithins (E 322) in the infant
formulae for infants below 16
weeks of age (FC 13.1.1) and in
special formulae for infants of that
age under special medical
conditions (FC 13.1.5.1), as well as
analytical data on the additive in
these formulae and analytical data
on choline in these formulae added
as nutrient.
• information on the percentage of
phosphatidylcholine content (mass
%) in specific lecithins
preparations used as food additive
E 322 in the infant formulae for
infants below 16 weeks of age
Received Assessed, no
further follow-up
19 Available online: https://www.efsa.europa.eu/en/consultations/call/call-technical-and-toxicological-data-lecithins-e-322-uses-
foods
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(FC 13.1.1), as well as in special
formulae for infants of that age
under special medical conditions
(FC 13.1.5.1);
• information on the fate and the
reaction products of lecithins (E
322) in the infant formulae for
infants below 16 weeks of age, as
well as in special formulae for
infants of that age under special
medical conditions;
• information on particular
specification requirements for
identity and purity of lecithins (E
322) (e.g. with respect to the
origin of lecithins (E 322) from soy
or eggs and to levels of protein
residues; content of toxic
elements) when used as food
additive in the infant formulae for
use in infants below 16 weeks of
age, as well as in special formulae
for infants of that age under
special medical conditions.
Analytical data on impurities in the
final special formulae for infants
below 16 weeks of age need to be
provided when no legal limit has
been established.
In addition, data should be provided
demonstrating the absence of Cronobacter
(Enterobacter) sakazakii in the food
additive.
2. Toxicological data A developmental neurotoxicity study
according to current OECD TG 426 is
required. In the study, the concentration
of metabolites of lecithins (e.g. choline) in
the dams milk should be determined.
Conclusions on the possible need of
additional studies within the frame of the
EFSA Guidance of the Scientific Committee
on the risk assessment of substances
present in food intended for infants below
16 weeks of age can be drawn as soon as
the results of the OECD TG 426 are made
available
Furthermore, the following information on
the toxicological properties of lecithins (E
322) and its adverse effects relevant for
its use in formulae and foods for special
medical purposes (FSMP) for infants below
16 weeks is required:
• post-marketing surveillance reports
on adverse reactions, including
allergic reactions, indicating the














provided and the data
from the post-
marketing surveillance
studies do not allow to
make firm conclusions
on the safety of
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the exposed infants and the use
levels of lecithins (E 322) in the
marketed products, where the
infant formulae and FSMPs are
already in use;
• published and unpublished case
reports, e.g. available
nutrivigilance data, on adverse or
undesired effects, including allergic
reactions, associated with the oral
administration of lecithins in any
form to infants.
Additional existing studies, including
confidential reports, if available:
• studies on toxicokinetics
(absorption, distribution,
metabolism in particular related to
choline production, excretion) in
the neonatal and young organism
compared with the adult;
• special studies aimed to identify
potential effects of exposure
during life stages in experimental
animals of relevance to human
infants e.g. extended one-
generation reproductive toxicity
study, repeated dose study on
neonatal animals;
• special studies aimed at
investigating effects on nutrient
availability;
• other relevant studies (human
data, including clinical and
epidemiological studies).
and in line with the
recommendations from




approach to be taken
for the safety
assessment of lecithins
(E 322) as food
additive in infant
formula used in infants
below the age of 16
weeks was to compare
the concentration of
choline in human milk




Literature searches should be conducted
relevant for the safety evaluation of
lecithins (E 322) when used in foods for
infants below 16 weeks of age up to the
date of the data submission, as described
in the Guidance for submission for food
additive evaluations (see its Section 5.3)
Received Assessed, no
further follow-up
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Appendix B – Phospholipids and choline levels in infant formulae and
maternal milk (Documentation provided to EFSA n. 2,3)
Phospholipids and choline levels in infant formulae
The mean concentration and standard deviation (SD) of phospholipids in maternal milk were
calculated based on data from the literature (Hibberd et al., 1982; Bitman et al., 1986; Sala-Vila et al.,
2005; Garcia et al., 2011, 2012; Giuffrida et al., 2013; Thakkar et al., 2013; Ma et al., 2017; Cheong
et al., 2018; Jiang et al., 2018; Ingvordsen Lindahl et al., 2019; McJarrow et al., 2019; Wei et al.,
2019; Wu et al., 2019; Documentation provided to EFSA n. 2,3). Overall, the total phospholipid levels
reported at the mean in colostrum, transitional milk and mature milk were calculated to average at
450, 382 and 248 mg/L, respectively, whereas maximum reported levels at the mean were of 1,173,
955 and 575 mg/L, respectively, see Table B.1.
For all three stages of lactation, the maximum mean level for total phospholipids was reported in
preterm infants in the same study (Ingvordsen Lindahl et al., 2019). Median total phospholipid levels in
maternal milk were reported in a single study (Giuffrida et al., 2016), at 330, 285 and 242 mg/L in
colostrum, transitional and mature milk, respectively. Maximum total phospholipids levels reported to
occur in colostrum, transitional and mature milk were of 1,600, 900 and 815 mg/L, respectively. In all
studies that evaluated total phospholipids in maternal milk during the various stages of lactation, total
phospholipids generally decreased in maternal milk as lactation progressed (Bitman et al., 1986; Sala-
Vila et al., 2005; Garcia et al., 2011; Thakkar et al., 2013; Giuffrida et al., 2016; Ma et al., 2017;
Ingvordsen Lindahl et al., 2019; McJarrow et al., 2019; Wei et al., 2019). Contradictory results are
reported with regard to total phospholipid levels by gestational age, whereby Ingvordsen Lindahl et al.
(2019) reported significantly higher levels in the milk of mothers who delivered preterm vs term infants
during all stages of lactation, whereas Wei et al. (2019) reported no significant difference.
Phospholipids and choline levels in infant formulae
The content of phospholipids and choline levels in infant formulae is reported in Table B.2, (from
Documentation provided to EFSA n. 3).
Choline levels in maternal milk
Mean concentration and SD of choline in maternal milk were also calculated by one interested
business operator based on the data from the literature, see Table B.3.
Table B.1: Total phospholipid levels in maternal milk
Lactation stage
Total phospholipids (mg/L)
Mean (avg)(a) Mean (max)(b) Median Max
Colostrum 450 1,173 330 1,600
Transitional Milk 382 955 285 900
Mature Milk 248 575 242 815
Avg: average; Max: maximum.
(a): Average of the reported mean maternal milk levels across studies.
(b): Maximum reported mean maternal milk level across studies.
Table B.2: Mean concentration and SD of lecithins and choline in formulae (n = 20)


















428 450 225 166 12 50
Overall SD 387 388 26 37 8 17
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